Community-Acquired Pneumonia

In the Clinic6 October 2009Community-Acquired PneumoniaChristine Laine, MD, MPH, Sankey Williams, MD, and Michael Niederman, MDChristine Laine, MD, MPH, Sankey Williams, MD, and Michael Niederman, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-7-200910060-01004 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Editor's Note: This issue of In the Clinic has been updated.Community-acquired pneumonia (CAP) can vary from a mild outpatient illness to a more severe disease requiring admission to a hospital or even an intensive care unit (ICU). Along with influenza, CAP is the eighth leading cause of death in persons older than age 65 in the United States and is the leading cause of death from infectious diseases. In contrast to hospital-acquired pneumonia, CAP occurs in the community. This distinction is becoming increasingly blurred because persons in contact with health care environments, such as nursing homes and chronic hemodialysis ...References1. American Lung Association. Trends in pneumonia and influenza morbidity and mortality, July 2007. Accessed at www.lungusa.org/atf/cf/%7B7a8d42c2-fcca-4604-8ade-7f5d5e762256%7D/ALA_LDD08_INFLUENZA_FINAL.PDF on 24 August 2009. Google Scholar2. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000;342:681-9. [PMID:10706897] Google Scholar3. Walker FJ, Singleton RJ, Bulkow LR, et al. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin Infect Dis. 2005;40:1730-5. [PMID:15909258] Google Scholar4. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747-55. [PMID:12724480] Google Scholar5. Fisman DN, Abrutyn E, Spaude KA, et al. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis. 2006;42:1093-101. [PMID:16575726] Google Scholar6. Bender JM, Ampofo K, Korgenski K, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis. 2008;46:1346-52. [PMID:18419434] Google Scholar7. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 1995;123:518-27. [PMID:7661497] Google Scholar8. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331:778-84. [PMID:8065407] Google Scholar9. Centers for Medicare & Medicaid Services. Hospital Quality Initiative Overview. Accessed at www.cms.hhs.gov/HospitalQualityInits/Downloads/Hospitaloverview.pdf on 24 August 2009. Google Scholar10. Nelson JC, Jackson ML, Weiss NS, et al. New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors. J Clin Epidemiol 2009; 62: 687-694. Google Scholar11. Toronto Invasive Bacterial Disease Network. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis. 2005;40:1288-97. [PMID:15825031] Google Scholar12. de Roux A, Marcos MA, Garcia E, et al. Viral community-acquired pneumonia in nonimmunocompromised adults. Chest. 2004;125:1343-51. [PMID:15078744] Google Scholar13. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749-59. [PMID:15858184] Google Scholar14. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 2002;162:1849-58. [PMID:12196083] Google Scholar15. El-Solh AA, Pietrantoni C, Bhat A, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med. 2003;167:1650-4. [PMID:12689848] Google Scholar16. Carratalà J, Mykietiuk A, Fernández-Sabé N, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med. 2007;167:1393-9. [PMID:17620533] Google Scholar17. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis. 2000;31:383-421. [PMID:10987698] Google Scholar18. Graffelman AW, le Cessie S, Knuistingh Neven A, et al. Can history and exam alone reliably predict pneumonia? J Fam Pract. 2007;56:465-70. [PMID:17543257] Google Scholar19. Hopstaken RM, Witbraad T, van Engelshoven JM, et al. Inter-observer variation in the interpretation of chest radiographs for pneumonia in community-acquired lower respiratory tract infections. Clin Radiol. 2004;59:743-52. [PMID:15262550] Google Scholar20. Syrjälä H, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis. 1998;27:358-63. [PMID:9709887] Google Scholar21. Metersky ML, Ma A, Bratzler DW, et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med. 2004;169:342-7. [PMID:14630621] Google Scholar22. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax. 2005;60:672-8. [PMID:16061709] Google Scholar23. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84-93. [PMID:16603606] Google Scholar24. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med. 2005;118:384-92. [PMID:15808136] Google Scholar25. GenIMS Investigators. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med. 2008;52:48-58.e2. [PMID:18342993] Google Scholar26. Infectious Diseases Society of America. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72. [PMID:17278083] Google Scholar27. Liapikou A, Ferrer M, Polverino E, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis. 2009;48:377-85. [PMID:19140759] Google Scholar28. Graham WG, Bradley DA. Efficacy of chest physiotherapy and intermittent positive-pressure breathing in the resolution of pneumonia. N Engl J Med. 1978;299:624-7. [PMID:355879] Google Scholar29. Li JZ, Winston LG, Moore DH, et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007;120:783-90. [PMID:17765048] Google Scholar30. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278:2080-4. [PMID:9403422] Google Scholar31. Kanwar M, Brar N, Khatib R, et al. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest. 2007;131:1865-9. [PMID:17400668] Google Scholar32. Feldman RB, Rhew DC, Wong JY, et al. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. Arch Intern Med. 2003;163:1718-26. [PMID:12885688] Google Scholar33. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA. 1997;278:32-9. [PMID:9207335] Google Scholar34. Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003;123:1503-11. [PMID:12740267] Google Scholar35. Mart'nez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003;36:389-95. [PMID:12567294] Google Scholar36. Lujan M, Gallego M, Fontanals D, et al. Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit Care Med. 2004;32:625-31. [PMID:15090938] Google Scholar37. International Pneumococcal Study Group. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003;37:230-7. [PMID:12856216] Google Scholar38. Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175:1086-93. [PMID:17332485] Google Scholar39. Metersky ML, Ma A, Houck PM, et al. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest. 2007;131:466-73. [PMID:17296649] Google Scholar40. Rello J, Catalán M, D'az E, et al. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med. 2002;28:1030-5. [PMID:12185421] Google Scholar41. International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004;170:440-4. [PMID:15184200] Google Scholar42. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest. 2005;128:2732-8. [PMID:16236949] Google Scholar43. Salluh JI, Verdeal JC, Mello GW, et al. Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med. 2006;32:595-8. [PMID:16552616] Google Scholar44. Salluh JI, P—voa P, Soares M, et al. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care. 2008;12:R76. [PMID:18547407] Google Scholar45. PROWESS Clinical Evaluation Committee. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med. 2005;33:952-61. [PMID:15891319] Google Scholar46. Fishbane S, Niederman MS, Daly C, et al. The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia. Arch Intern Med. 2007;167:1664-9. [PMID:17698690] Google Scholar47. Musher DM, Rueda AM, Kaka AS, et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45:158-65. [PMID:17578773] Google Scholar48. Rhew DC, Hackner D, Henderson L, et al. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest. 1998;113:142-6. [PMID:9440581] Google Scholar49. Nathan RV, Rhew DC, Murray C, et al. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med. 2006;119:512.e1-7. [PMID:16750965] Google Scholar50. El Solh AA, Aquilina AT, Gunen H, et al. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. J Am Geriatr Soc. 2004;52:224-9. [PMID:14728631] Google Scholar51. Falguera M, Mart'n M, Ruiz-González A, et al. Community-acquired pneumonia as the initial manifestation of serious underlying diseases. Am J Med. 2005;118:378-83. [PMID:15808135] Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCorrection: In the Clinic: Community-Acquired Pneumonia Metrics Cited byManagement of pneumoniaImpact of pre-hospital antibiotic use on community-acquired pneumoniaPneumoniaVitamin D Status and Community-Acquired Pneumonia: Results from the Third National Health and Nutrition Examination SurveyThe role of vitamin D supplementation in the risk of developing pneumonia: three independent case–control studiesAddition of Vitamin D Status to Prognostic Scores Improves the Prediction of Outcome in Community-Acquired PneumoniaPopulation-based cohort study of outpatients with pneumonia: rationale, design and baseline characteristicsBiomarkers define the clinical response to dexamethasone in community-acquired pneumoniaCommunity-Acquired Pneumonia: An Unfinished BattleComparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysisAmiodaroneThe Viriato StudyCommunity Acquired Pneumonia 6 October 2009Volume 151, Issue 7Page: ITC4-1KeywordsAntibioticsInfectious diseasesIntensive care unitsMedical risk factorsPathogensPneumoniaSputumThoraxVaccines ePublished: 6 October 2009 Issue Published: 6 October 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.